TNGX logo

TANGO THERAPEUTICS INC

TNGXNASDAQ
🏆 #1468 by market capUS Equity
$22.65▲ $0.42 (+1.89%)
Latest quote
🔔
Track TNGX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.9%
7d▼ 18.9%
14d▼ 0.3%
30d▼ 7.4%
ytd▲ 155.4%
1y▲ 190.3%
🏦Market Cap
$3.82B
Small Cap
📈Revenue Growth (YoY)
121.5%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
56.4x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$22.38 – $23.57
52-Week Range
$7.37 – $34.39
Volume (shares)
81,231
Avg Volume (shares)
—
Shares Outstanding
168.6M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$62M
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
56.4x
EPS (TTM)
$-0.84
Dividend Yield
—
Dilution (1yr)
+6.9%
TNGX logo

TANGO THERAPEUTICS INC

TNGX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$62M▲ +48.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.3%▼ −3.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$111M▼ −23.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$140M▲ +5.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
116.2M▲ +6.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$79M▲ +$46M YoY
StockOtter · stockotter.space

About TANGO THERAPEUTICS INC

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.